An excerpt of this months editorial is included below followed by the August index.
This journal is an official digital educational resource from the American Association for the Study of Liver Diseases. Along with full text access, each article includes a video presentation and author interview.
This journal is an official digital educational resource from the American Association for the Study of Liver Diseases. Along with full text access, each article includes a video presentation and author interview.
Clinical Liver Disease
Special Issue: Editorial, Palliative Care & Non-Viral Liver Infections
Volume 6, Issue 2, pages 27–29, August 2015
Overview of palliative care and hospice services (pages 30–32)
Issues in the end-stage liver disease patient for which palliative care could be helpful (pages 33–36)
Working with palliative care services (pages 37–40)
Amebic liver abscess (pages 41–43)
Recognizing clonorchiasis: A foodborne illness leading to significant hepatobiliary disease (pages 44–46)
Hepatosplenic candidiasis (pages 47–50)
Pyogenic liver abscess (pages 51–54)
Volume 6, Issue 2, pages 27–29, August 2015
Hepatitis C treatment: Back to the warehouse
John P. Rice M.D
Article first published online: 24 AUG 2015
DOI: 10.1002/cld.490
Hepatitis C treatment: Back to the warehouse
Like many physicians that specialize in hepatitis C virus (HCV) treatment, I have spent the last few years advising many of my patients with chronic HCV infection to defer treatment and wait for new therapies. For those without advanced fibrosis or an extraintestinal manifestation of HCV, this process of “warehousing” patients for future HCV treatment made perfect sense. Why undergo interferon-based therapy, with all of the side effects and marginal results, when it was becoming clear that highly efficacious, interferon-free therapy was close to becoming a reality? Patients, advocacy groups, and physicians closely followed the development of sofosbuvir (Sovaldi), simeprevir (Olysio), sofosbuvir/ledipasvir (Harvoni), and paritaprevir/ritonavir/ombitasvir/dasabuvir (Viekira Pak) among others in eager anticipation of US Food and Drug Administration (FDA) approval and, for most patients, the possibility of a cure of their HCV infection.
John P. Rice M.D
Article first published online: 24 AUG 2015
DOI: 10.1002/cld.490
Like many physicians that specialize in hepatitis C virus (HCV) treatment, I have spent the last few years advising many of my patients with chronic HCV infection to defer treatment and wait for new therapies. For those without advanced fibrosis or an extraintestinal manifestation of HCV, this process of “warehousing” patients for future HCV treatment made perfect sense. Why undergo interferon-based therapy, with all of the side effects and marginal results, when it was becoming clear that highly efficacious, interferon-free therapy was close to becoming a reality? Patients, advocacy groups, and physicians closely followed the development of sofosbuvir (Sovaldi), simeprevir (Olysio), sofosbuvir/ledipasvir (Harvoni), and paritaprevir/ritonavir/ombitasvir/dasabuvir (Viekira Pak) among others in eager anticipation of US Food and Drug Administration (FDA) approval and, for most patients, the possibility of a cure of their HCV infection.
Watch a video presentation of this article
Index
Hepatitis C treatment: Back to the warehouse (pages 27–29)Overview of palliative care and hospice services (pages 30–32)
Issues in the end-stage liver disease patient for which palliative care could be helpful (pages 33–36)
Working with palliative care services (pages 37–40)
Amebic liver abscess (pages 41–43)
Recognizing clonorchiasis: A foodborne illness leading to significant hepatobiliary disease (pages 44–46)
Hepatosplenic candidiasis (pages 47–50)
Pyogenic liver abscess (pages 51–54)
No comments:
Post a Comment